Loading
iRANO adds one rule to the brain tumour response criteria for immunotherapy: growth on MRI in the first six months should be confirmed on a later scan if the patient is not clearly worse.
Immunotherapy can cause delayed responses and treatment-induced inflammation that look like progression on brain imaging. A RANO panel (Okada and colleagues, Lancet Oncology 2015) recommended that when imaging meets RANO progression, including new lesions, within six months of starting immunotherapy, progression should be confirmed on follow-up imaging provided the patient is not significantly worse clinically. The criteria also cover corticosteroid use. RANO 2.0 later folded the confirmation idea into the main criteria.
Showing the technology this term belongs to: MRI.
Shares RANO criteria (brain tumour response), Complete response (CR) and partial response (PR), MRI, Glioma & glioblastoma.
Shares iRECIST (response criteria for immunotherapy trials), Progressive disease and radiographic progression, Complete response (CR) and partial response (PR), Immune checkpoint inhibitors.
Shares RANO criteria (brain tumour response), MRI.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares MRI, Glioma & glioblastoma.
Shares MRI, Glioma & glioblastoma.
Shares MRI, Glioma & glioblastoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/